Skip to main content
. 2021 Aug 8;40(12):1579–1588. doi: 10.1016/j.healun.2021.07.026

Table 2a.

Demographic and Clinical Characteristics of Heart and Lung Transplant Recipients With Stratification by Antibody Response to a Two-Dose Course of SARS-CoV-2 Messenger RNA Vaccine

HT recipient vaccine response, No. (%)
Priming dose responders Booster responders Non-responders
n = 19 n = 64 n = 51
Age group, ya
 18-39 7 (24) 9 (31) 13 (45)
 40-59 7 (18) 20 (53) 11 (29)
 ≥60 5 (8) 34 (52) 27 (41)
Sexb
 Male 9 (14) 34 (52) 22 (34)
 Female 9 (13) 30 (45) 28 (42)
Racec
 White 17 (14) 59 (49) 44 (37)
 Non-white 2 (16) 5 (38) 6 (46)
Time since transplant, y
 <3 4 (11) 10 (26) 24 (63)
 3-6 6 (15) 19 (46) 16 (39)
 7-11 3 (15) 13 (65) 4 (20)
 ≥12 6 (17) 22 (63) 7 (20)
Type of regimen
 Includes anti-metabolite maintenance immunosuppressiond 7 (8) 41 (47) 40 (45)
 Does not include anti-metabolite maintenance immunosuppression 12 (26) 23 (50) 11 (24)
Vaccine
 mRNA-1273 (Moderna) 12 (19) 29 (45) 23 (36)
 BNT16b2 (Pfizer-BioNTech) 7 (10) 35 (50) 28 (40)

HT, Heart transplant.

a

Missing data for 1 participant.

b

Missing data for 2 participants.

c

Missing data for 1 participant.

d

Antimetabolite maintenance immunosuppressive regimens included mycophenolate mofetil, mycophenolic acid, and azathioprine.